Background: Surgical resection is standard treatment for colorectal and neuroendocrine liver metases provided the tumor can be removed completely. The same is true for isolated pulmonary metastases. To date, only few reports have addressed the value of surgical resection of organ metastases from other solid tumors.
INTRODUCTION
Curative treatment of primary solid tumors is still the domain of surgery. For metastatic lesions, however, the role of surgery is more controversial. Almost half a century ago hepatic resection was reported as a treatment for metastatic gastric cancer. Since then, the benefit of hepatic resection for metastatic colorectal cancer has been investigated extensively and long-term survival can now be expected in a substan-tial number of patients (1, 2). Today hepatic resection is performed with low operative mortality and morbidity, and, therefore, represents the treatment of choice for metastatic lesions (3, 4). Long-term survival has also been observed after hepatic resection for metastatic neuroendocrine tumors (5-8).
The role of surgery in the treatment of non-colorectal non-neuroendocrine (NCNN) liver metastases is less clear, since these tumors are either rare or recurrence is typically extensive, precluding a potentially curative local approach. Still, a few studies have summarized experience with surgical treatment of hepatic metastases from NCNN (Table 1) (5, (9) (10) (11) (12) (13) . These observations suggest, that the benefit from hepatic resection in selected patients with metastatic NCNN may be similar to that for patients with colorectal carcinoma at approximately 20 to 30 % 5-year survival ( Table 1) .
The first pulmonary resection for metastatic disease was performed by Divis 1927 (14), but from 1940 to the mid-1960s, pulmonary metastasectomy was performed only in highly selected patients. Surgical treatment was considered only, if the patient had a long disease-free interval following resection of the primary tumor, and had only few lesions confined to one lung. Despite the apparent paradox of local resection for a systemic disease, however, subsequent experience from several institutions suggested that more liberal indications for pulmonary metastasectomy were appropriate (15). Although several reports have examined a large number of patients with pulmonary metastatic disease (16), experience with pulmonary metastases from NCNN has remained limited in most institutions (17) (18) (19) (20) (21) . The aim of the present review is, therefore, to determine the value of liver and lung resection for metastases from noncolorectal and non-neuroendocrine (NCNN) malignancies.
MATERIAL AND METHODS
The literature was searched by Medline, conference proceedings and cross-referencing of published articles for information pertaining to the long-term results of surgical treatment of non-colorectal and non-neuroendocrine (NCNN) liver or lung metastases.
RESULTS

HEPATIC METASTASECTOMY FOR NCNN LIVER METASTASES
Apart from colorectal and neuroendocrine primary tumors almost all other primary tumors sites have been candidates for resection of liver or pulmonary metastasis. Among the heterogeneous group of so called NCNN metastases most reports relate to the resection of metastases from breast and stomach cancer as well as sarcomas.
Breast Cancer
Liver metastases develop in approximately one half of women with metastatic breast cancer (22, 23). They are typically associated with tumor deposits at other sites, indicating advanced tumor stage and poor prognosis (median survival < 6 months) (22, 23). Therefore, hepatic resection in this group of patients is rarely performed. However, in a small proportion of patients with breast cancer (~1 %), solitary liver metastasis is the only site of metastasis. Even in this minority of patients the prognosis is dismal and survival of more than two years is rare (5, (22) (23) (24) . This may explain why most physicians view liver metastases from breast cancer with resignation. Some surgical centers, however, have advocated more active approaches, including liver resection (Table 2) (11, (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) .
In the largest series published hepatic resection for metastatic breast cancer was performed in fifty-two patients of which 86 % were resected curatively (22). With a median follow-up period of 23 months after surgery (1-72 months) survival was 86 % at 12 months, 79 % at 24 months and 49 % at 36 months. The 3-year survival rate after resection of hepatic metastasis was better (82 % vs. 45 %), when the interval from primary tumor resection exceeded 48 months.
Another study enrolled 17 women who underwent hepatic resection with curative intent for metastatic breast cancer (23). After a follow-up of up to12 years 7 of the 17 patients were still alive and four of these patients are still free of tumors after 6 and 17 months, 6 and 12 years. The actuarial 5-year survival rate in this study was 22 %. The best outcome was found when liver metastases developed more than 1 year after resection of the primary tumor regardless of the lymph node status at the time of the primary breast cancer resection. The authors concluded from these data that favorable 22 % long-term survival can be achieved with metastasectomy in a selected group of patients.
A third study found a similar 5-year survival of 35 % in patients who underwent a potentially curative resection (11). The median survival after curative liver resection was 38 months compared to only 3 months after incomplete removal of liver metastases.
Sarcoma
Numerous therapeutic modalities for patients with liver metastasis from sarcoma are applied including chemotherapy, ablation, or partial hepatectomy. Chemotherapy is used most frequently although this approach did not improve survival (32-34). Now, there is increasing evidence that resection of hepatic metastasis from sarcoma is beneficial for these patients, similar to resection of lung metastasis for this disease (Table 2) (9, 11, 12, 29, 32, (35) (36) (37) .
The largest study to date reported a 5-year survival rate of 30 % in 56 patients after liver resection for metastatic sarcoma (32). It should be noted, that these 56 patients were selected from 331 patients with hepatic metastasis from sarcoma. The greatest survival benefit was seen, when liver metastasis were detected more than two years after resection of the primary tumor. A 5-year survival rate of 20 % was also reported by another study with 18 patients (11). According to recent studies with overall 104 patients reported a cumulative 5-year survival rate of > 20 % can be achieved in a selected subgroup of patients particularly those with a long interval (> 2 years) from primary tumor treatment (9, 11, 12, 32, 35-37).
Gastric cancer
A number of studies have analyzed the outcome of surgical removal of hepatic metastasis from gastric carcinoma (Table 2) (5, 9, 11, (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) . As in breast cancer only a minority of patients with liver metastases of gastric carcinoma is eligible for hepatic resection (~2 %), because the majority of patients present with multiple, bilobar metastases and often with a combination of peritoneal dissemination, lymph node or other distant metastases (50). As disappointing the survival in some studies appeared to be (37, 40, 44, 46, 49) ( Table 2 ). Taking into account that the natural course of metastatic gastric cancer is disastrous, it appears that a subset of patients benefits from hepatic resection, chiefly those with solitary, metachronous metastases.
Melanomas
The present review identified a total of 50 patients undergoing hepatic resection for malignant melanoma in five different studies (9, 11, 36, 37, 51).
In the largest series, 34 patients of 1750 patients (2 %) with hepatic metastasis from melanoma underwent explorative celiotomy (51). Hepatic resection was performed in 24 patients and 18 patients had a complete tumor removal. For these 24 patients the median survival time was 28 months compared with only 4 months for patients who underwent exploration only. The overall 5-year survival rate was 29 %.
Similar data were published in a study with 10 hepatic resections in 9 patients with metachronous hepatic metastases from malignant melanoma (Table 1) (11). Seven of 9 primary tumors were ocular melanomas and only 2 of the 9 were melanomas of the extremities. The 5-year survival rate for all patients (5 with R0 resection, 5 with grossly positive resection margins) in this series was 22 %, with a 5-year survival rate of 50 % after complete (R0) resection (11).
Renal cell carcinoma
Resection of metachronous hepatic metastases from renal cell carcinoma is clinically challenging, since metastases often occur years after removal of the primary tumor (11, 12, 52, 53). The largest study presented 17 patients with liver lesions from renal cell carcinoma (52). The 13 resectable patients had a median survival of 16 months compared to only 4 months for patients with unresectable disease.
In a comparable series of 13 patients, 12 underwent R0 resection (11). Those curatively resected patients had a median survival of 27 months and a 5-year survival rate of 9 % compared to 14 months after R1/ 2 resection.
Pancreatic and lung cancer
The role of hepatic surgery for metastatic adenocarcinoma of the pancreas is limited. None of the published studies has observed a survival benefit (Table 2) (5, 9, 54). In the case of metachronous hepatic metastases of pancreatic cancer a surgical approach is exceptionally rare, e.g. those patients in whom the primary tumor has been resected a long time ago. In a minority of patients, however, with single synchronous metastasis hepatic resection may be appropriate if the primary tumor is also curatively resectable and hepatic resection does not increase the operative risk (54, 55).
Resectability of hepatic metastases from lung cancer is similarly limited and only a few reports have been published (5, 11, 37).
The largest study analyzed 6 patients, who underwent hepatic resection for lung cancer metastases. No median survival benefit was documented for these patients although long term survival of 185 months has been reported for one patient following resection of hepatic metastases from lung cancer (11). Based on the present literature it is impossible to determine the potential role of surgery in a multimodality therapeutic concept. However, patients with a solitary metastasis detected long after the primary tumor resection may be considered for surgery in the absence of alternative effective treatment.
PULMONARY METASTASECTOMY FOR NCNN METASTASES
As for liver metastasis pulmonary metastasectomy should only be performed when the tumor is completely resectable. The preoperative assessment should therefore include a chest x-ray and a high resolution spiral CT scan of the chest. The spiral CT scan identified 42 % more nodules compared to standard contrast-enhanced CT scans (56). Increased identification of smaller nodules, however, reduces specificity for cancer (57). The likelihood that a new pulmonary nodule is a metastasis as opposed to a second primary cancer is directly related to the original type of malignancy (58). In patients with a primary lung cancer, a new pulmonary nodule may present a second primary cancer (59). Therefore, if nonsurgical treatment is considered, it is important to establish a definitive diagnosis before initiating therapy and not simply to assume that the patient has metastatic disease.
Indication for surgery in tumors responsive to chemotherapy
Indication for surgery should take into account the effectiveness of alternative treatment modalities, which should be reviewed by a team including medical oncologists and radiation therapists.
Dramatic improvements in the chemotherapy of breast cancer have rendered pulmonary metastasectomy an uncommon form of therapy. Except for patients with a solitary nodule, most patients would be treated non-surgically (60). Advances in the systemic therapy of osteogenic sarcoma influenced indication for surgery in a multi-disciplinary approach. Also metastatic germ cell cancer is primarily treated systemically. Pulmonary resection is nowadays restricted to the removal of residual tumor and to identify residual vital tumor cells (61).
Indications for surgery in tumors not responsive to systemic therapy
For renal cell carcinoma, gynecologic cancers, various types of head and neck cancers, malignant melanoma, colorectal cancer and soft tissue sarcomas pulmonary metastasectomy is recommended. Occasionally metastatic disease requires treatment more urgently than the primary tumor. The requirements for a potentially curative operation are, therefore, as follows:
1. the metastases seem to be resectable 2. general and functional risks are justifiable 3. the primary tumor should be treated or treatable.
The precondition of no demonstrable extrapulmonary metastatic sites is no longer maintained, because combined operations can be performed either simultaneously or as staged procedures. However, wider experience is needed regarding the long term prognosis of patients undergoing surgical treatment for multilocular metastatic disease. The removal of multiorgan metastases from non-colorectal non-neuroendocrine tumors should be reserved for selected patients which may benefit from revision of several body cavities for simultaneous resection of pulmonary and e.g. abdominal metastases (62).
Criteria for selecting patients for pulmonary metastasectomy:
1. disease-free interval, 2. tumor doubling time, 3. presence of mediastinal/hilar lymph node metastases, 4. number of pulmonary metastases.
Technical aspects of pulmonary metastasectomy
The choice of incision via standard thoracotomy is preferred in patients with pulmonary metastases confined to one lung on preoperative spiral CT scan. Bilateral lesions require sternotomy or the clamshell incision. Video-assisted thoracoscopy is not suitable for pulmonary metastasetomy, if complete resection is planned, because of potential inaccuracy of the pre-operative CT scan and the inability to palpate the inflated lung (63). Single-lung ventilation is recommended to ensure adequate palpation of the lung. Resection should preserve as much of the healthy lung tissue as possible, to allow subsequent resections in selected patients for recurrent pulmonary metastases.
In patients with curatively resectable pulmonary metastases, the number of metastases should have only a limited influence on surgical decision making (64). The role of lymph node dissection in pulmonary metastasectomy remains controversial, since the prognostic relevance of lymph node involvement for long term survival is unclear. The overall mortality rate reported for pulmonary metastasectomy is less than 2 % (16, 62).
Survival following pulmonary metastasectomy in selected NCNN solid tumors Breast cancer and nonovarian gynecologic cancer
In breast and nonovarian gynecologic carcinomas, pulmonary metastasectomy is only one part in a multidisciplinary regime. In highly selected patients 5-year survival rates of 31 to 50 % are seen (Table 3) (60, 65-67). Multi-disciplinary therapy makes it difficult to evaluate surgery alone in pulmonary metastasectomy for breast and nonovarian gynecologic cancers, however for some patients surgery may be beneficial (68-70).
Soft tissue sarcoma
For pulmonary resection five-year survival rate between 23 and 35 % have been reported (20, 21, 71-80). Prognostic relevance was demonstrated for disease free interval > 6 to 12 months, and less than three metastases showed a trend toward a higher five-year overall survival, whereas unfavorable factors included the histologic variants of liposarcoma and malignant peripheral nerve tumors and patient age older than 50 years at the time of treatment of metastasis (79, 80). Even in recurrent disease to the lung surgical resection of pulmonary metastases may be warranted (69, 81).
Osteogenic sarcoma
The beneficial role of complete pulmonary metastasectomy is reflected in 5-year survival rates between 20 to 50 % (71, 78, 82-84). Complete surgical resection, the number of metastases, the duration of the free interval and the degree of tumor differentiation were favorable prognostic factors (84). Although adjuvant chemotherapy may also be of benefit, long term survival is best achieved by complete surgical resection of pulmonary metastases (85, 86).
Gastric cancer and hepatocellular carcinoma
Only a few reports are published for resection of pulmonary metastases from metastatic gastric or hepatocellular carcinoma (87-89). An aggressive surgical approach is not warranted in patients with pulmonary metastases from gastric or hepatocellular cancer, but in a few selected patients pulmonary resection may be beneficial (87-89).
Head and neck cancer
Isolated pulmonary metastases from head and neck cancer are potentially curable by surgical resection, if the primary lesion is under control and pulmonary metastases can be resected completely. In this situation 5-year survival rates between 24 to 54 % are reported after resection of pulmonary metastases (90-94). Survival is influenced by the cell type, the site of origin of the primary tumor and again a long interval between primary treatment and the diagnosis of pulmonary metastases (90-94).
Malignant melanoma
Surgical treatment of lung metastases from melanoma remains controversial as the expected outcome is much poorer than for other primary tumors and a reliable system for selecting patients is not available (95,96). In most series good results were obtained for patients with one or two lesions. Only a few series reported 5-year survival rates of approximately 25 % (67, 97-100). Prognosis is better in patients with a long disease free interval, solitary metastasis and complete tumor resection (95, 100, 101).
Renal cell carcinoma
Surgery remains the only potentially curative treatment for patients with limited metastatic renal cell carcinoma. Several studies reported a 5-year survival rate between 21 to 60 % (Table 3 ) (102-106). Complete resection, tumor size of less than 4-cm in diameter, tumor-free lymph nodes at the time of primary tumor operation and a long disease free intervall (DFI), were favourable prognostic factors (102) (103) (104) (105) (106) . Recurrence of resectable pulmonary metastases does not impair survival, thus suggesting repeated resection in patients with recurrent disease (105) .
Testicular carcinoma
Metastatic testicular cancer is best treated by a multi-disciplinary approach. After chemotherapy residual pulmonary masses may be detectable on a CT scan, which may represent either necrosis, mature teratoma, or viable cancer. If complete resection of remaining pulmonary metastases is possible almost 85 % of the patients are long-term survivors (107) (108) (109) . Adverse prognostic factors include metastases to nonpulmonary visceral sites and the presence of viable carcinoma in the resected specimen (107) (108) (109) .
CONCLUSION
Surgical resection allows a potentially curative approach for selected patients with liver and lung metastases and 5-year survival exceeding 25 % can be expected for patients with colorectal carcinoma (110, 111) or neuroendocrine tumors (7, 8). The present review indicates that similar survival rates can be achieved for some patients with hepatic or pulmonary metastases from NCNN tumors (5, 12, 13, 79, 106). Future studies will have to determine prognostic factors in patients with non-colorectal non-neuroendocrine liver or lung metastases to identify those patients, which will benefit most from surgical treatment. Also, the potential role of multimodal therapy will have to be examined. At present, because effective chemotherapy or radiotherapy is not available for most patients with metastatic NCNN malignancy and because operative treatment carries a low risk, liver and lung resection should also be considered for all patients with technically resectable metastases. Even in apparently unfavorable situations complete tumor resection is associated with long term survival in a fair number of patients, which otherwise would be denied a chance for cure (112) . The same is true for repeated metastasectomy, which should be consequently pursued as it carries a similarly low operative risk and may result in long term survival, if not cure, in some patients, for which effective alternative treatment is not available (81). 
